___

• Al-Majed, AA., Gado, AM., Al-Shabanah, OA., Mansour, MA.(2002). Alpha-lipoic acid ameliorates myocardial toxicity induced by Doksorubisin. Pharmacol Res,46:499-503.
• Altieri, P., Spallarossa, P., Barisione, C., Garibaldi, S., Garuti, A., Fabbi, P., Ghigliotti, G., Brunelli, C.(2012). Inhibition of Doksorubisin-Induced Senescence by PPARδ Activation Agonists in Cardiac Muscle Cells: Cooperation between PPARδ and Bcl6. PLoS One, 7(9):e46126. doi: 10.1371/journal.pone.0046126.
• Bates, SE., Rosing, DR., Lobins, RL.(2006). Challenges of evaluating the cardiac effects of anticancer agents. Clin Cancer Res, 12: 3871.
• Berthiaume, J., Wallace, K. (2007). Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol. Toxicol. 23, 15–25. Billingham, ME., Mason, JW., Bristow, MR., Daniels, JR.(1978). Antracycline cardiomyopathy monitered by morphologic changes. Cancer Treat Rep, 62: 865.
• Bristow, M., Sageman, W.S, Scott, R.H., Billingham, M.E., Bowden, R.E., Kernoff, R.S., Snidow, I.H., Daniel, J.R.(1980). Acute and chronic cardiovascular effects of doxorubicin in the dog: The cardiovascular pharmacology of drug-induced histamine release. J. Cardiovasc. Pharmacol., 2; 487-515.
• Carvalho, RA., Sousa, RP., Cadete, VJ., Lopaschuk, GD., Palmeira, CM., Bjork, JA. et al.(2010). Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy. Toxicology, 270: 92–98.
• Childs, A.C., Phaneuf, S. L., Dirks, A. J., Phillips, T., & Leeuwenburgh, C.(2002). Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio. Cancer research, 62(16), 4592-4598.
• Cortes-Funes, H., Coronado C. ( 2007). Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol, 7:56–60.
• Cummings, J., Willmott, N., Smyth, J.(1991). The molecular pharmacology of doxorubicin in vivo. Eur J Cancer, 27: 532-535.
• Deng, S., Kruger, A., Kleschyov, AL., Kalinowski, L., Daiber, A., Wojnowski, L.(2007). Gp91phox containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH. Free Radic Biol Med, 42: 466–473.
• Deng, S., Yan, T., Jendrny, C., Nemecek, A., Vincetic, M., Gödtel-Armbrust, U., & Wojnowski, L. (2014). Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms. BMC cancer, 14(1), 842.
• Fogli, S., Nieri, P., Breschi, M.C. (2004). The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 18,664–675.
• Fridovich I.(1995). Superoxide radical and superoxide dismutases. Annu. Rev. Biochem.64, 97–112.
• Galluzzi, L., Joza, N., Tasdemir, E., et al.(2009). No death without life: vital function of apoptotic effectors. Cell Death Differ, 16:1093–1107.
• Gilleron, M., Marechal, X., Montaigne, D., Franczak, J., Neviere, R., Lancel, S.(2009). NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis. Biochem Biophys Res Commun, 388: 727–731.
• Giorgio, M., Menna, P., Salvatorelli, E., Cairo, G., Gianni, L.(2004). Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacol Rev, 56:185-229.
• Goffart, S., von Kleist-Retzow, J.-C., Wiesner, R.J.(2004). Regulation of mitochondrial proliferation in the heart: power-plant failure contributes to cardiac failure in hypertrophy. Cardiovasc. Res. 64, 198–207.
• Goodman Gilman A. (2006). Goodman & Gilman's The Pharmacological Basis of Therapeutics. Eleventh edition. McGraw-Hill Medical Publishing Division, chapter: 51; 1358-1359.
• Goormaghtigh, E., Chatelain, P., Caspers, J., Ruysschaert, JM.(1980). Evidence of a complex between adriamycin derivatives and cardiolipin: possible role in cardiotoxicity. Biochem Pharmacol, 29: 3003–3310.
• Gu, J., Song, ZP., Gui, DM., Hu, W., Chen, YG., Zhang, DD.(2012). Resveratrol Attenuates Doksorubisin-Induced Cardiomyocyte Apoptosis in Lymphoma Nude Mice by Heme Oxygenase-1 Induction. Cardiovasc Toxicol., 12(4):341-349. Horenstein, MS., Vander Heide, RS., L'Ecuyer, TJ.(2000). Molecular basis of anthracyclineinduced cardiotoxicity and its prevention. Mol Genet Metab, 71: 436–444.
• Huber, SA.(1990). Doxorubicin-induced alterations incultured myocardial cells stimulate cytolytic T-lymphocyte responses. Am J Pathol, 137: 449-456.
• Ichikawa, Y., Ghanefar, M., Bayeva, M., Wu, R., Khechaduri, A., Prasad, S.V.N., Mutharasan, R.K., Naik, T.J., Ardehali, H. (2014). Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J. Clin. Investig. 124(2), 617-630.
• Jain D. (2000). Cardiotoxicity of doxorubicin and other anthracycline derivatives. J Nucl Cardiol, 7: 53–62.
• Janbabai, G., Nabati, M., Faghihinia, M., Azizi, S., Borhani, S., & Yazdani, J. (2017). Effect of enalapril on preventing anthracycline-induced cardiomyopathy. Cardiovascular toxicology, 17(2), 130-139.
• Jordon, MA.(2002). Anti-cancer agents. Cur Med Chem, 2:1–17.
• Kim, S. Y., Kim, S. J., Kim, B. J., Rah, S. Y., Chung, S. M., Im, M. J., & Kim, U. H. (2006). Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes. Experimental & Molecular Medicine, 38(5), 535-545.
• L’Ecuyer T, Sanjeev S, Thomas R et al (2006) DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol 291:H1273–H1280.
• Lebrecht, D., Walker, UA. (2007). Role of mtDNA lesions in anthracycline cardiotoxicity. Cardiovasc Toxicol 7:108–113.
• Li, J., Wang, P. Y., Long, N. A., Zhuang, J., Springer, D. A., Zou, J., ...&Hwang, P. M. (2019). p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities. Proceedings of the National Academy of Sciences, 116(39), 19626-19634.
• Liu, B., Bai,, QX., Chen, XQ., Gao, GX., Gu, HT.(2007). Effect of curcumin on expression of survivin, Bcl-2 and Bax in human multiple myeloma cell line. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 15: 762–766.
• Ma, J., Wang, Y., Zheng, D., Wei, M., Xu, H., Peng, T.(2013). Rac1 signalling mediates Doksorubisin-induced cardiotoxicity through both reactive oxygen species-dependent and-independent pathways. Cardiovasc Res, 1;97(1):77-87.
• Minotti, G., Recalcati, S., Menna, P., et al.(2004). Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms. Methods Enzymol, 378: 340-361.
• Moens, AL., Leyton-Mange, JS., Niu, X., Yang, R., Cingolani, O., Arkenbout, EK. et al.(2009). Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor. J Mol Cell Cardiol, 47: 576–585.
• Morishima, I., Okumura, K., Matsui, H. et al. (1999). Zinc accumulation in adriamycin-induced cardiomyopathy in rats: effects of cardioprotective antioxidant. J Pineal Res, 26: 204-210.
• Mukhopadhyay, P., Rajesh, M., Bátkai, S., Kashiwaya, Y., Hasko, G., Liaudet, L., ... & Pacher, P. (2009). Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. American Journal of Physiology-Heart and Circulatory Physiology, 296(5), H1466-H1483.
• Nabati, M., Janbabai, G., Baghyari, S., Esmaili, K., & Yazdani, J. (2017). Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity. Journal of Cardiovascular Pharmacology, 69(5), 279-285.
• Neilan, TG., Blake, SL., Ichinose, F., Raher, MJ., Buys, ES., Jassal, DS.(2007). Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation, 116: 506–514.
• Nishiyama, K., Yasue, H., Moriyama, Y. et al.(2001). Acute effects of melatonin administration on cardiovascular autonomic regulation in healty men. Am Heart J, 141: 149.
• Nitobe, J., Yamaguchi, S., Okuyama, M., Nozaki, N., Sata, M., Miyamoto, T., et al. (2003). Reactive oxygen species regulate FLICE inhibitory protein (FLIP) and susceptibility to Fas mediated apoptosis in cardiac myocytes. Cardiovasc Res, 57: 119–128.
• Octavia, Y., Tocchetti, C.G., Gabrielson, K.L., Janssens, S., Crijns, H.J., Moens, A.L. (2012). Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J. Mol. Cell. Cardiol. 52, 1213–1225.
• Oliveira, PJ., Wallace, K.B. (2006). Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats-relevance for mitochondrial dysfunction. Toxicology, 220; 160-168.
• Olson, R.D., Mushlin, P.S. (1990). Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 4, 3076–3086.
• Outomuro, D., Grana, DR., Azzato, F., Milei J.(2007). Adriamycine – induced myocardial toxicity: New solutions for an old problem? Int J Cardiol, 12: 117(1):6-15.
• Ozgen, Z. E., Erdinc, M., Akkoc, H., & Kelle, I. (2016). Protective effects of melatonin on doxorubicin induced cardiotoxicity in isolated rat heart. Eastern Journal of Medicine, 21(3), 119.
• Pacher, P., Liaudet, L., Bai, P., et al. (2003). Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation, 107: 896–904.
• Pani, G., Bedogni, B., Anzevino, R., Colavitti, R., Palazzotti, B., Borrello, S., Galeotti, T. (2000). Deregulated manganese superoxide dismutase expression and resistance to oxidative injury in p53-deficient cells. Cancer Res. 60, 4654–4660.
• Pereira, G.C., Silva, A.M., Diogo, C.V., Carvalho, F.S., Monteiro, P., Oliveira, P.J.(2011). Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol. Curr. Pharm. Des. 17, 2113–2129.
• Reiter, RJ. (1992). The aging pineal and its physiological consequences. BioEssay, 14: 169- 175.
• Sacco, G., Bigioni, M., Lopez, G., Evangelista, S., Manzini, S., Maggi, C.A.(2009). ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat. Vasc. Pharmacol. 50, 166–170.
• Sahna, E., Parlakpinar, H., Ozturk, F., Ozer, M.K., Ozugurlu, F., Acet, A. (2003).Melatonin protects against myocardial doxorubicin toxicity in rats: Role of physiological concentrations. J Pineal Res,35: 257-261.
• Schlame, M., Rua, D., Greenberg, ML. (2000). The biosynthesis and functional role of cardiolipin. Prog Lipid Res, 39: 257–288.
• Schwebe, M., Ameling, S., Hammer, E., Monzel, J. V., Bonitz, K., Budde, S., ... & Poesch, A. (2015). Protective effects of endothelin receptor A&B inhibitors against doxorubicin-induced cardiomyopathy. Biochemical pharmacology, 94(2), 109-129.
• Shi, Y., Moon, M., Dawood, S., McManus, B., Liu, P.(2011). Mechanisms and management of doxorubicin cardiotoxicity. Herz 36, 296–305.
• Simunek, T., Sterba, M., Popelova, O., Adamcova, M., Hrdina, R., Gersl, V. (2009). Anthracycline induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep, 61: 154–171.
• Singal, PK., Iliskovic N.(1998). Doxorubicin-induced cardiomyopathy. N Engl J Med, 339: 900.
• Sishi, BJ., Loos, B., Van Rooyen, J., Engelbrecht, AM. (2013). Autophagy upregulation promotes survival and attenuates Doksorubisin-induced cardiotoxicity. Biochem Pharmacol., 1;85(1):124-134.
• Suliman, HB., Carraway, MS., Ali, AS., Reynolds, CM., Welty-Wolf, KE., Piantadosi, CA. (2007). The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. J Clin Invest, 117: 3730–3741.
• Thorn, CF., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, TE., Altman, RB. (2011). Doxorubicin pathways: pharmacodynamics and adverse effects, Pharmacogenet. Genomics, 21:440–446.
• Tong, J., Ganguly, P.K, Singal, P.K. (1991). Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am. J. Physiol, 260; 909-916.
• Ueno, M., Kakinuma, Y., Yuhki, K., Murakoshi, N., Iemitsu, M., Miyauchi, T. et al. (2006). Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J Pharmacol Sci., 101: 151–158.
• Vasquez-Vivar, J., Martasek, P., Hogg, N., Masters, BS., Pritchard Jr, KA., Kalyanaraman, B. (1997). Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry, 36: 11293–11297.
• Walker, J. R., Sharma, A., Lytwyn, M., Bohonis, S., Thliveris, J., Singal, P. K., & Jassal, D. S. (2011). The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity. Journal of the American Society of Echocardiography, 24(6), 699-705.
• Wallace, KB. (2007). Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol 7:101–107.
• Weiss RB. (1992). The anthracyclines: will we ever find a better doxorubicin? Semin Oncol, 19:670–686.
• Xu, MF., Tang, PL., Qian, ZM. (2001). Ashraf M. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci, 68: 889–901.
• Ying, W. (2008). NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal, 10: 179-206.
• Youn, HJ., Kim, HS., Jeon, MH., Lee, JH., Seo, YJ., Lee, YJ. et al. (2005). Induction of caspase independent apoptosis in H9c2 cardiomyocytes by adriamycin treatment. Mol Cell Biochem., 270: 13–19.
• Yu, X., Ruan, Y., Huang, X., Dou, L., Lan, M., Cui, J., ... & Sun, S. (2020). Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes. Biochemical and Biophysical Research Communications, 523(1), 140-146.
• Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L. S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. (2012). Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nature medicine, 18(11), 1639-1642.
• Zhao, L., Zhang, B. (2017). Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci. Rep. 7, 44735.
• Zucchi, R., Danesi R. (2003). Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem,3: 151-171.